Indian Pharma Shares Tread Water Amid Trump’s 200% Tariff Signal

Pharmaceutical stocks remained largely flat on Wednesday, July 16, even as U.S. President Donald Trump hinted at the possible imposition of tariffs on drug imports by the end of the month. Trump’s comments have placed the global pharmaceutical sector, especially Indian drug exporters, under intense scrutiny.

Indian Pharma Under Pressure Amid U.S. Tariff Threats

As of writing this news, the Nifty Pharma index showed a down movement by 0.21% at 22,618.15, reflecting investor caution. While select stocks like Biocon, Natco Pharma, and IPCA Labs saw gains of up to 3.5%, major players like Divi’s Labs and Cipla dragged the index down.

Speaking to the media on Tuesday, Trump revealed his intention to begin with “low tariffs” on imported pharmaceuticals, with a sharp increase to follow within a year or so. "We're going to start with a low tariff and give the pharmaceutical companies a year or so to build, and then we’re going to make it a very high tariff,” he stated.

Invest in Indian Markets and Unlock Future Potential With 5paisa!

Open Account Now

Earlier this month, he had indicated that the levies could eventually rise to as much as 200%, targeting companies that fail to onshore their manufacturing to the U.S.

This move is part of a broader trade agenda, which includes potential tariffs on semiconductors and copper. Trump’s administration has already initiated a Section 232 investigation, citing concerns that foreign pharmaceutical imports may threaten U.S. national security.

Indian pharma exporters—key suppliers of generic drugs to the U.S.—are expected to feel the brunt of this shift. Many companies operate on thin margins and rely heavily on the U.S. market. A steep tariff hike could make it unfeasible to export at current prices, potentially forcing some companies to halt production, resulting in drug shortages in the American market.

Industry Sounds Alarm Over Supply Chain and Pricing Fallout

Analysts are raising alarms. UBS noted that the 12–18 month grace period proposed by the U.S. administration would be “insufficient” for companies to shift manufacturing operations to American soil, which typically takes four to five years. Blackrock warned of severe consequences for both businesses and consumers: “A 200% tariff would inflate production costs, compress profit margins, and risk supply chain disruptions.”

Even a 25% tariff could increase U.S. drug prices by nearly $51 billion annually, according to PhRMA. Industry voices are labelling the proposal “counterproductive” to improving healthcare outcomes. Meanwhile, investment leaders like Afsaneh Beschloss of RockCreek Group described the potential fallout as “disastrous.”

Some global and U.S.-based pharmaceutical giants—like Novartis, Sanofi, Roche, Eli Lilly, and Johnson & Johnson—have already pledged increased investments in the U.S. to counter the looming trade risks.

Conclusion

As the world awaits clarity on the Section 232 findings due later this month, the pharmaceutical industry is entering a phase of high uncertainty. If implemented, the tariffs could reshape the global drug supply chain, disrupt Indian pharma exports, and significantly drive up medication costs for U.S. consumers. Until then, drugmakers are bracing for impact and planning across multiple scenarios.